Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Cipla
Chubb
Colorcon
UBS

Generated: May 25, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,753,706

« Back to Dashboard

Which drugs does patent 5,753,706 protect, and when does it expire?

Patent 5,753,706 protects AURYXIA and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: 5,753,706
Title: Methods for treating renal failure
Abstract:Methods of controlling phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a ferric-containing compound selected from the group consisting of ferric citrate, ferric acetate, and combinations thereof. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.
Inventor(s): Hsu; Chen Hsing (Ann Harbor, MI)
Assignee:
Application Number:08/794,328
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,753,706
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 5,753,706
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 5,753,706

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y CONTROL OF SERUM PHOSPHOROUS LEVELS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 5,753,706

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 400264 ➤ Try a Free Trial
Australia 5441998 ➤ Try a Free Trial
Australia 723091 ➤ Try a Free Trial
Canada 2272711 ➤ Try a Free Trial
Germany 69738824 ➤ Try a Free Trial
Denmark 0959878 ➤ Try a Free Trial
European Patent Office 0959878 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Daiichi Sankyo
Medtronic
Federal Trade Commission
US Department of Justice
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.